Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257204 · ClinicalTrials.gov registry record · Phase 2
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT01257204: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01257204 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 196 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01257204, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.
Primary Outcome
SVR24 was defined as undetectable HCV RNA (HCV RNA \<lower limit of quantitation \[LLOQ\], target not detected \[TND\]) at follow-up Week 24. The LLOQ was 25 IU/mL, and \<LLOQ, TND was 10 IU/mL. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.
Interventions
- DRUG Placebo
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG Pegylated interferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT01257204 record still lists
NCT01257204 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01257204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01257204 about?
NCT01257204 is a clinical study titled "Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection". To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.
What is the current status of trial NCT01257204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2010-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01257204?
The interventions under investigation include: Placebo (DRUG), Ribavirin (DRUG), Daclatasvir (DRUG), Pegylated interferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01257204?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01257204's enrollment target sits among peer trials
196 349th of 2000 higher than 1,651 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia